Anti-mesothelin chimeric antigen receptor T cell therapy - Marino BiotechnologyAlternative Names: Anti-mesothelin CAR T cells therapy - Marino Biotechnology
Latest Information Update: 19 Oct 2016
At a glance
- Originator Marino Biotechnology
- Class Antineoplastics; CAR-T cell therapies
- Mechanism of Action Cytotoxic T lymphocyte stimulants; T lymphocyte replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 01 Aug 2016 Phase-I clinical trials in Cancer (Recurrent, Metastatic disease, Late-stage disease, Second-line therapy or greater) in China (IV) (NCT02930993)